CL2016000495A1 - Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades. - Google Patents
Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades.Info
- Publication number
- CL2016000495A1 CL2016000495A1 CL2016000495A CL2016000495A CL2016000495A1 CL 2016000495 A1 CL2016000495 A1 CL 2016000495A1 CL 2016000495 A CL2016000495 A CL 2016000495A CL 2016000495 A CL2016000495 A CL 2016000495A CL 2016000495 A1 CL2016000495 A1 CL 2016000495A1
- Authority
- CL
- Chile
- Prior art keywords
- triazolo
- pyrimidine
- inflammation
- pain
- diseases
- Prior art date
Links
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical compound N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 208000002193 Pain Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
COMPUESTOS DERIVADOS DE TRIAZOLO[4,5-D]PIRIMIDINA; PROCESO DE PREPARACIÓN; COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE Y EL USO PARA EL TRATAMIENTO O PROFILAXIS DEL DOLOR, ATEROSCLEROSIS, INFLAMACIÓN, DIABETES MELLITUS, ENTRE OTRAS ENFERMEDADES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13183385 | 2013-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016000495A1 true CL2016000495A1 (es) | 2016-10-07 |
Family
ID=49111076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016000495A CL2016000495A1 (es) | 2013-09-06 | 2016-03-04 | Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9593123B2 (es) |
| EP (3) | EP3943497A1 (es) |
| JP (1) | JP6441356B2 (es) |
| KR (3) | KR20220140651A (es) |
| CN (1) | CN105555788B (es) |
| AR (1) | AR097553A1 (es) |
| AU (1) | AU2014317229B2 (es) |
| CA (1) | CA2915766C (es) |
| CL (1) | CL2016000495A1 (es) |
| CR (1) | CR20160076A (es) |
| DK (2) | DK3041843T3 (es) |
| EA (1) | EA028335B1 (es) |
| ES (2) | ES2714094T3 (es) |
| HR (2) | HRP20190361T1 (es) |
| HU (2) | HUE055201T2 (es) |
| IL (1) | IL243092B (es) |
| LT (2) | LT3041843T (es) |
| MA (1) | MA38826B1 (es) |
| MX (2) | MX367084B (es) |
| MY (1) | MY191628A (es) |
| PE (2) | PE20191528A1 (es) |
| PH (1) | PH12016500250B1 (es) |
| PL (2) | PL3483163T3 (es) |
| PT (2) | PT3483163T (es) |
| RS (2) | RS58390B1 (es) |
| SG (1) | SG11201601714UA (es) |
| SI (2) | SI3483163T1 (es) |
| TR (1) | TR201900662T4 (es) |
| TW (1) | TWI705966B (es) |
| UA (1) | UA116395C2 (es) |
| WO (1) | WO2015032769A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015162630A1 (en) * | 2014-04-25 | 2015-10-29 | Anlon Chemical Research Organization | Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis. |
| JP6669743B2 (ja) | 2014-11-07 | 2020-03-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | カンナビノイド受容体２のアゴニストとしてのトリアゾロ［４，５−ｄ］ピリミジン |
| WO2017004133A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2017076266A1 (zh) * | 2015-11-06 | 2017-05-11 | 江苏恒瑞医药股份有限公司 | 制备坎格雷洛中间体的方法 |
| CN109311895B (zh) | 2016-06-23 | 2021-06-18 | 豪夫迈·罗氏有限公司 | 新型[1,2,3]三唑并[4,5-d]嘧啶衍生物 |
| EP3475280B1 (en) | 2016-06-23 | 2020-04-08 | H. Hoffnabb-La Roche Ag | Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives |
| WO2018015088A1 (en) | 2016-06-23 | 2018-01-25 | F. Hoffmann-La Roche Ag | Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives |
| CN109348716A (zh) * | 2016-06-23 | 2019-02-15 | 豪夫迈·罗氏有限公司 | 对2型大麻素受体具有亲和力的[1,2,3]三唑并[4,5-d]嘧啶衍生物 |
| CN106478639B (zh) * | 2016-09-05 | 2018-09-18 | 郑州大学 | 嘧啶并1,2,4–三氮唑类的lsd1抑制剂、其制备方法及应用 |
| CN106432247B (zh) * | 2016-09-27 | 2018-06-29 | 郑州大学 | 含有腙键的嘧啶并三氮唑类化合物、制备方法及其应用 |
| CN106432248B (zh) * | 2016-09-27 | 2018-11-27 | 郑州大学 | 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用 |
| CN106928296A (zh) * | 2017-02-06 | 2017-07-07 | 上海华升生物科技有限公司 | 一种2‑(3,3,3‑三氟丙硫基)腺苷的合成方法 |
| CN106928235A (zh) * | 2017-05-03 | 2017-07-07 | 郑州大学 | 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用 |
| CN107033148B (zh) * | 2017-05-03 | 2018-10-26 | 郑州大学 | 含嘧啶并三氮唑—巯基四氮唑类lsd1抑制剂、其制备方法及应用 |
| CN109516990B (zh) * | 2017-09-19 | 2021-06-01 | 天津药物研究院有限公司 | 嘧啶并三氮唑类化合物、其制备方法和用途 |
| CN113582935A (zh) * | 2021-08-27 | 2021-11-02 | 中国医学科学院放射医学研究所 | 一种炎症小体核苷酸结合寡聚化结构域样受体蛋白3抑制剂及其制备方法和应用 |
| CN115246832B (zh) * | 2022-06-15 | 2024-05-24 | 深圳湾实验室 | 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用 |
| CN119912457B (zh) * | 2025-03-03 | 2025-10-10 | 郑州大学 | 嘧啶并三氮唑类化合物及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999011643A1 (en) | 1997-09-02 | 1999-03-11 | Du Pont Pharmaceuticals Company | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
| US6653304B2 (en) | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
| WO2006009698A2 (en) * | 2004-06-17 | 2006-01-26 | The Regents Of The University Of California | Antagonizing an adenosine a2a receptor to amelioriate one or more components of addictive behavior |
| AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| EP2155747B1 (en) | 2007-05-10 | 2012-10-24 | GE Healthcare Limited | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US9271962B2 (en) | 2008-03-17 | 2016-03-01 | Northeastern University | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors |
| WO2010120987A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| EP2771326B1 (en) | 2011-10-27 | 2017-12-20 | LEK Pharmaceuticals d.d. | Synthesis of triazolopyrimidine compounds |
| UA111640C2 (uk) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
| US9067943B2 (en) * | 2011-11-25 | 2015-06-30 | Hoffmann-La Roche Inc. | [1,2,3]triazolo[4,5-D]pyrimidine derivatives |
| KR20150027824A (ko) | 2012-07-04 | 2015-03-12 | 에프. 호프만-라 로슈 아게 | 칸나비노이드 수용체 2 작용제로서 신규한 아다만틸 유도체 |
| MX2015007156A (es) | 2012-12-07 | 2015-10-14 | Hoffmann La Roche | Piridina-2-amidas utiles como agonistas receptores de canabinoides 2 (cb2). |
| SG10201800170YA (en) | 2012-12-07 | 2018-02-27 | Hoffmann La Roche | Novel pyridine derivatives |
| RS55951B1 (sr) | 2012-12-07 | 2017-09-29 | Hoffmann La Roche | Derivati pirazina kao agonisti cb2 receptora |
| CA2885987A1 (en) | 2012-12-07 | 2014-06-12 | F. Hoffmann-La Roche Ag | Pyridine-2-amides useful as cb2 agonists |
| JP6514119B2 (ja) | 2013-03-07 | 2019-05-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規ピラゾール誘導体 |
| PE20151977A1 (es) | 2013-05-02 | 2016-01-07 | Hoffmann La Roche | Nuevos derivados de purina |
| KR20160002857A (ko) | 2013-05-02 | 2016-01-08 | 에프. 호프만-라 로슈 아게 | CB2 수용체 작용제로서의 피롤로[2,3-d]피리미딘 유도체 |
| KR20160018543A (ko) | 2013-06-11 | 2016-02-17 | 에프. 호프만-라 로슈 아게 | 신규한 테트라졸론 유도체 |
-
2014
- 2014-09-03 KR KR1020227034655A patent/KR20220140651A/ko not_active Ceased
- 2014-09-03 CN CN201480048593.7A patent/CN105555788B/zh active Active
- 2014-09-03 HU HUE18206943A patent/HUE055201T2/hu unknown
- 2014-09-03 UA UAA201603048A patent/UA116395C2/uk unknown
- 2014-09-03 SG SG11201601714UA patent/SG11201601714UA/en unknown
- 2014-09-03 PL PL18206943T patent/PL3483163T3/pl unknown
- 2014-09-03 PL PL14761320T patent/PL3041843T3/pl unknown
- 2014-09-03 JP JP2016539509A patent/JP6441356B2/ja active Active
- 2014-09-03 ES ES14761320T patent/ES2714094T3/es active Active
- 2014-09-03 PT PT182069435T patent/PT3483163T/pt unknown
- 2014-09-03 PE PE2019001869A patent/PE20191528A1/es unknown
- 2014-09-03 DK DK14761320.2T patent/DK3041843T3/en active
- 2014-09-03 EA EA201690478A patent/EA028335B1/ru not_active IP Right Cessation
- 2014-09-03 HU HUE14761320A patent/HUE041760T2/hu unknown
- 2014-09-03 TR TR2019/00662T patent/TR201900662T4/tr unknown
- 2014-09-03 SI SI201431869T patent/SI3483163T1/sl unknown
- 2014-09-03 KR KR1020167008516A patent/KR102349567B1/ko active Active
- 2014-09-03 WO PCT/EP2014/068640 patent/WO2015032769A1/en not_active Ceased
- 2014-09-03 DK DK18206943.5T patent/DK3483163T3/da active
- 2014-09-03 KR KR1020217017887A patent/KR102454344B1/ko active Active
- 2014-09-03 CA CA2915766A patent/CA2915766C/en active Active
- 2014-09-03 AU AU2014317229A patent/AU2014317229B2/en active Active
- 2014-09-03 EP EP21179163.7A patent/EP3943497A1/en active Pending
- 2014-09-03 LT LTEP14761320.2T patent/LT3041843T/lt unknown
- 2014-09-03 PE PE2015002700A patent/PE20160691A1/es unknown
- 2014-09-03 ES ES18206943T patent/ES2883923T3/es active Active
- 2014-09-03 MX MX2016002117A patent/MX367084B/es active IP Right Grant
- 2014-09-03 RS RS20190264A patent/RS58390B1/sr unknown
- 2014-09-03 EP EP14761320.2A patent/EP3041843B1/en active Active
- 2014-09-03 RS RS20211007A patent/RS62234B1/sr unknown
- 2014-09-03 MX MX2019009100A patent/MX391724B/es unknown
- 2014-09-03 SI SI201431099T patent/SI3041843T1/sl unknown
- 2014-09-03 EP EP18206943.5A patent/EP3483163B1/en active Active
- 2014-09-03 PT PT14761320T patent/PT3041843T/pt unknown
- 2014-09-03 HR HRP20190361TT patent/HRP20190361T1/hr unknown
- 2014-09-03 LT LTEP18206943.5T patent/LT3483163T/lt unknown
- 2014-09-03 MY MYPI2016700721A patent/MY191628A/en unknown
- 2014-09-04 AR ARP140103305A patent/AR097553A1/es active IP Right Grant
- 2014-09-04 TW TW103130651A patent/TWI705966B/zh active
-
2015
- 2015-12-14 IL IL243092A patent/IL243092B/en active IP Right Grant
-
2016
- 2016-02-04 PH PH12016500250A patent/PH12016500250B1/en unknown
- 2016-02-04 MA MA38826A patent/MA38826B1/fr unknown
- 2016-02-16 CR CR20160076A patent/CR20160076A/es unknown
- 2016-02-23 US US15/050,753 patent/US9593123B2/en active Active
- 2016-03-04 CL CL2016000495A patent/CL2016000495A1/es unknown
-
2021
- 2021-08-16 HR HRP20211322TT patent/HRP20211322T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016000495A1 (es) | Compuestos derivados de triazolo[4,5-d]pirimidina, agonistas de receptor cb2; proceso de preparación; composición que los comprende y el uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamación, diabetes mellitus, entre otras enfermedades. | |
| CL2014001174A1 (es) | Compuestos derivados de [1,2,3]triazolo[4,5-d]pirimidina y sus sales, como agonistas del receptor de canabinoides 2; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamacion, glaucoma, ataque isquemico transitorio, entre otras enfermedades. | |
| CL2014002412A1 (es) | Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras. | |
| CL2019000941A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| CL2015002386A1 (es) | Nuevos octahidro-pirrolo[3,4-c)-pirrol y -piridina-fenilo. | |
| CL2015003686A1 (es) | Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| ECSP17007538A (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| CL2015002635A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| CL2014001103A1 (es) | Compuestos derivados de heteroaril piridona y aza-piridona sustituidas, inhibidores de btk quinasa; composicion farmaceutica que los comprende; proceso de preparacion de la composicion farmaceutica; kit farmaceutico; y uso para el tratamiento de trastornos inmunes, cancer, inflamacion, trastornos neurologicos, entre otros. | |
| MX380829B (es) | Derivados de quinoxalina útiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa. | |
| CL2014000956A1 (es) | Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor. | |
| CL2015001538A1 (es) | Compuestos derivados de piridin-2-amidas, agonistas cb2; proceso de preparacion; composicion farmaceutica que los contiene; su uso para el tratamiento o profilaxis del dolor, aterosclerosis, retinopatia diabetica, glaucoma, diabetes mellitus, entre otras. | |
| CL2015002546A1 (es) | Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos | |
| CO2017002160A2 (es) | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| CL2011001464A1 (es) | Compuestos derivados de purina, agonistas del receptor cb2; composicion farmaceutica que los comprende; y uso del compuesto para tratar el dolor osteoartritico. | |
| CL2014001309A1 (es) | Compuestos derivados de [1,2,3] triazolo [4,5-d]-pirimidina, agonistas del receptor de canabinoides 2; proceso de obtencion; composicion farmaceutica; uso para el tratamiento o la profilaxis del dolor, aterosclerosis,retinopatia diabetica, diabetes, fibrosis hepatica, fallo cardiaco, entre otras. | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| CL2015003195A1 (es) | Derivados de purina como agonistas del receptor cb2. | |
| UY36003A (es) | Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina. | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| NI201700078A (es) | Pirazolpiridinaminas | |
| MX2018004295A (es) | Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar. | |
| CL2015003196A1 (es) | Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2. | |
| CR20160016A (es) | Pirazolpiridinas sustituidas |